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AUY954There is no known antiviral drug treatment that routinely terminates persistent virus infections. A recent
provocative report indicated that low dosage of the sphingosine analog FTY720 caused lymphopenia in mice
persistently infected with lymphocytic choriomeningitis virus (LCMV)-clone 13 (Cl 13) and induced viral
clearance within 30 days post-treatment (Premenko-Lanier et al., 2008). However, we ﬁnd that low dosage
of FTY720 fails to purge LCMV-Cl 13 infection and does not induce lymphopenia in LCMV-Cl 13-infected
mice. In fact, infection with non-persistent LCMV-Arm53b or with persistent LCMV-Cl 13 induces an
equivalent lymphopenia, demonstrating that the quantity of circulating cells has little bearing on viral
persistence. In addition, treatment with FTY720 or the sphingosine-1-phosphate receptor 1 (S1P1)-speciﬁc
agonist, AUY954, does not alleviate T cell exhaustion and exacerbates disruption of the CD8+ T cells response
following LCMV-Cl 13 infection. Therefore, treatment with a sphingosine analog does not ameliorate
persistent LCMV-Cl 13 infection.
© 2009 Elsevier Inc. All rights reserved.Introduction
Humanpathogens suchashuman immunodeﬁciency virus, hepatitis
B and hepatitis C viruses induce inactivation of T cells, which leads to
persistent viral infection associatedwith the exhaustion (nonfunctional
activity) of virus-speciﬁc antiviral T cells (reviewed by Oldstone, 2009).
Such T cell exhaustion was ﬁrst reported using the experimental model
of persistent lymphocytic choriomeningitis virus (LCMV)-clone 13 (Cl
13) infection in its natural murine host (Moskophidis et al., 1993;
Wherry et al., 2003; Zajac et al., 1998). This model compares LCMV-Cl
13, a virus that induces persistence, with the parental strain, LCMV-
Armstrong 53b (Arm53b), that does not. These variants differ by 5
nucleotides which results in a coding change of 2 amino acids (aa)
(Salvato et al., 1988, 1991). The LCMV-Cl 13 aa changes include a
phenylalanine to leucine substitution at aa 260 of the glycoprotein and a
lysine to glutamine change at aa 1079 of the RNA polymerase protein
(Salvato et al., 1991). The receptor for LCMV and other old world
arenaviruses is α-dystroglycan (Cao et al., 1998) which among cells of
the immune system is preferentially located on dendritic cells (DC)
(Kunz et al., 2001; Sevilla et al., 2000). The glycoprotein (GP) mutation
of LCMV-Cl 13 dramatically increases the afﬁnity of the GP for the LCMV
receptor (Kunzet al., 2001),α-dystroglycan, two and ahalf logs over thene).
ll rights reserved.binding afﬁnity of the LCMV-Arm53b GP, resulting in an enhanced
dendritic cell tropism (Kunz et al., 2001; Sevilla et al., 2000). Due to
these observations, LCMV-Cl 13 has been used extensively to study the
molecular basis of immune suppression and subsequent viral persis-
tence (Ahmed et al., 1984; Barber et al., 2006; Brooks et al., 2006, 2008).
Recently the Altman lab (Premenko-Lanier et al., 2008) reported that
alteration of T cell trafﬁcking by low dosage of the sphingosine analog,
FTY720, was associated with the termination of persistent infection
induced by LCMV-Cl 13. According to this report (Premenko-Lanier et
al., 2008), the strong lymhopenia induced by the non-persistent LCMV-
Arm53b strain was mimicked by FTY720 treatment of LCMV-Cl 13-
infected mice and was the cause of viral clearance, although the
mechanism of how the drug achieved this was not uncovered.
Administration of sphingosine analogs results in the redistribution
of lymphocytes into secondary lymphoid organs (Mandala et al.,
2002), which can be mediated via activation of the S1P1 receptor
(Sanna et al., 2004). Due to the profound effect of these compounds on
lymphocyte localization, the drug has been tested as a treatment to
alter trafﬁcking of killer T lymphocytes in patients with solid graft
rejection (Nikolova et al., 2001) and multiple sclerosis (O'Connor et
al., 2009). FTY720 as well as other chemical modulators of the
sphingosine-1-phosphate (S1P) immunoregulatory axis can impair
the immune response following acute viral infections (Marsolais et al.,
2008, 2009). In this instance, local delivery of FTY720 analogs into the
airway inhibits migration and expansion of inﬂuenza virus-speciﬁc T
cells into the lung, the release of cytokines and chemokines in the lung
and antigen presentation by DC in the mediastinal lymph node and
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delivery of drug affects immunomodulation during viral infection,
although sequestration of normally expanding T cells in secondary
lymphoid organs occurs (Pinschewer et al., 2000).
In this report, we utilize the LCMV model to probe the effects of
sphingosine analogs on the lymphocyte response in both acute and
persistent infection. In addition, we test the relevance of sphingosine
analogs as therapeutic agents to treat a persistent infection. Our results
reveal that early or late treatment with a low dose of FTY720
(0.004 mg/kg) has no signiﬁcant effect on the outcome of persistent
virus infection. We ﬁnd that both LCMV-Cl 13 and -Arm53b induce
equivalent levels of lymphopenia during the acute phase of infection.
Induction of lymphopenia with FTY720 or the S1P1-speciﬁc agonist,
AUY954, does not alleviate T cell exhaustionor LCMV-Cl 13 persistence
and reduces the number of virus-speciﬁc T cells. Lastly, using inﬂuenza
virus, we observe that lymphopenia induced by systemic administra-
tion of AUY954 inhibits the generation of inﬂuenza virus-speciﬁc T
cells. Thus, it is clear that modulation of the S1P immunoregulatory
axis does not terminate persistent LCMV infection and instead can
adversely alter the antiviral immune T cell response.
Results
LCMV infection induces lymphopenia
We compared the extent of acute lymphopenia induced by the
LCMV variant -Cl 13 that causes a persistent infection with the
parental LCMV strain, LCMV-Arm53b, that results in a vigorousFig. 1. Lymphopenia occurs at equivalent levels following either LCMV-Arm53b or LCMV-Cl
causes a decrease in circulating CD4+ and CD8+ T cells on day 3 post-infection, when com
(shaded triangles) or -Cl 13 (shaded circles) exhibit an equivalent degree of lymphopenia reg
(D) T cells in the blood from infected mice are reduced on day 3 post-infection, compared
which represents the average number of cells±SEM. Four mice were used per group and dantiviral cytotoxic T lymphocyte (CTL) response, clears virus and does
not cause a persistent infection (Ahmed et al., 1984). Infection with
LCMV-Arm53b or -Cl 13 induces similar levels of lymphopenia
characterized by a reduced number of circulating CD4+ and CD8+ T
cells in the blood, when compared to uninfected mice (Fig. 1A). In
order to determine if lymphopenia depends on the infectious dose,
mice were infected with of 5×105, 1×106 and 2×106 PFU of either
LCMV-Arm53b or -Cl 13. Infection with either virus at any of the three
doses results in a profound reduction in the total number of cells
within the blood (Fig. 1B). Similarly, there is a decrease in numbers of
CD4+ and CD8+ T cells in the blood with both strains of virus, at all
infectious doses employed (Fig. 1C and D). These data are contra-
dictory to the previous study in which the extent of lymphopenia was
enhanced in LCMV-Arm53b-infected mice when compared to mice
infected with LCMV-Cl 13 (Premenko-Lanier et al., 2008). Thus, the
degree of lymphopenia following LCMV-Cl 13 and -Arm53b infections
is equivalent and does not differ due to the infectious dose
administered.
Treatment with FTY720 induces lymphopenia independently of virus
infection
Sphingosine analogs are effective at inducing lymphopenia. We
assessed if treatment with FTY720, a sphingosine analog, would
further enhance lymphopenia following LCMV-Cl 13 infection.
Infection with LCMV-Cl 13 results in a decrease in the frequencies
(Fig. 2A and B) and numbers (Fig. 2C and D) of CD4+ and CD8+ T cells
in the blood compared to uninfected mice on day 3 post-infection. An13 infection. (A) Infection with 2×106 PFU i.v. of either LCMV-Arm53b or LCMV-Cl 13
pared to uninfected mice. (B–D) Mice infected with varying doses of LCMV-Arm53b
ardless of virus strain or inoculation dose. Total number of cells (B), CD4+ (C) and CD8+
to uninfected mice. (B–D) Uninfected mice are represented by the shaded boxed area,
ata are represented as average±SEM.
Fig. 2. FTY720 induces lymphopenia in LCMV-Cl 13 infected and uninfected mice. (A–D) Mice were mock-infected (black lines, black squares) or infected with 2×106 PFU i.v. of
LCMV-Cl 13 (grey lines, grey circles) and treated with increasing doses of FTY720 at 1 h and 1 and 2 days post-infection. Mice were euthanized on day 3 post-infection and blood was
removed via cardiac puncture. Frequencies (A and B) and concentrations (C and D) of CD4+ (A and C) and CD8+ T cells in blood (B and D) are decreased by treatment with 67 and
1000 μg/kg of FTY720. Four mice were used per group and data are represented as average±SEM. ⁎, p≤0.05, signiﬁcantly different from uninfected. #, p≤0.05, signiﬁcantly
different from vehicle (dose 0).
262 K.B. Walsh et al. / Virology 397 (2010) 260–269earlier report by Premenko-Lanier et al. (2008) indicated that
intravenous (i.v.) treatment with a low dose of FTY720 (4 μg/kg)
was sufﬁcient to enhance lymphopenia in LCMV-Cl 13-infected mice.
However, we ﬁnd that administration of FTY720 (4 μg/kg) does not
signiﬁcantly alter the frequencies or numbers of circulating T cells
when compared to vehicle treatment (Fig. 2A–D). As expected, i.v.
treatment with a medium (67 μg/kg) or a high dose (1 mg/kg) of
FTY720 enhances lymphopenia in both LCMV-Cl 13-infected and
uninfected mice. The extent of lymphopenia observed between the
67 μg/kg and 1 mg/kg doses of FTY720 is equivalent between LCMV-
Cl 13-infected and uninfected mice, demonstrating that maximum
lymphopenia can be achieved with 67 μg/kg independently of virus
infection. In summary, our results show that treatment with a low
dose of FTY720 (4 μg/kg) does not enhance lymphopenia in
uninfected or LCMV-Cl 13-infected mice and the extent of lympho-
penia induced by medium (67 μg/kg) and high doses (1 mg/kg) of
FTY720 is equivalent between infected and uninfected mice. There-
fore, FTY720 does not synergize with virus-induced lymphopenia and
acts independently of viral infection.
FTY720 hinders the antiviral T cell immune response and does not alter
LCMV persistence
Premenko-Lanier et al. (2008) demonstrated that a low dose of
FTY720 (4 μg/kg) induced lymphopenia in LCMV-Cl 13-infected mice,
which induced viral clearance by preventing T cell exhaustion. Since
our study does not support induction of lymphopenia with 4 μg/kg of
FTY720, we also addressed the effect of FTY720 treatment on T cellexhaustion. Intravenous injection of 4 μg/kg of FTY720 to LCMV-Cl 13-
infected mice does not alter the frequency or number of virus-speciﬁc
CD8+ (Fig. 3A and B) or CD4+ (Fig. 3C and D) T cells in the spleen on
day 8 post-infection, when compared to mice treated with vehicle.
However, treatment with 1 mg/kg of FTY720 results in a dramatic
decrease in the number of splenocytes (data not shown)which results
in a signiﬁcant decrease in the numbers of LCMV-speciﬁc CD8+ (Fig.
3B) and CD4+ (Fig. 3D) T cells. In a control stain, streptavidin-APC by
itself did not bind splenocytes from infected mice demonstrating that
free streptavidin-APC does not artiﬁcially enhance the tetramer
positive signal. Analysis of cytokine production by peptide stimulation
reveals that CD8+ (Fig. 3E) and CD4+ (Fig. 3F) T cells from mice
infected with LCMV-Cl 13, regardless of FTY720 treatment, had
diminished cytokine proﬁles compared to mice infected with LCMV-
Arm53b. Treatment with 4 μg/kg of FTY720 does not affect the
number of IFN-γ producing CD8+ (Fig. 3G) of CD4+ (Fig. 3H) T cells
when compared to vehicle. However, treatment with 1 mg/kg
signiﬁcantly reduces IFN-γ producing LCMV-speciﬁc T cells which
correlates with the reduction in the total number of LCMV-speciﬁc
tetramer+ T cells (Fig. 3B and D). These data demonstrate that
treatment with 4 μg/kg FTY720 does not alleviate T cell exhaustion
and administration of a dose of FTY720 effective at inducing
lymphopenia (1 mg/kg) can adversely affect the antiviral immune
response, as defects in the T cell response were detectable even 5 days
after the last administration of FTY720. In correlation, treatment with
1 mg/kg of FTY720 results in a slight but signiﬁcant increase in viral
burden within the serum compared to vehicle-treated mice, while
treatment with 4 μg/kg does not alter viremia on days 15 and 30 post-
Fig. 3. FTY720 does not prevent T cell exhaustion or promote viral clearance, but impairs the T cell immunity in response to LCMV-Cl 13 infection. (A–H)Miceweremock infected (white bars), infectedwith 1×105 PFU LCMV-Arm53b i.p. (E and F
only) orwith 2×106 PFU LCMV-Cl 13 i.v. and treated i.v., once a day for 3 days, starting 1 h post-infectionwithwater (VEH; grey bars), 4 μg/kg (dashed bars) or 1mg/kg (black bars) of FTY720, and spleenswere harvested on day 8 post-infection.
(A–D) Frequencies of CD8+GP33–41 (A) andCD4+GP65–77 (C) tetramer positive cells are not altered by FTY720when compared to VEH. (B andD)Administration of 1mg/kg FTY720 signiﬁcantly reduces thenumbers of these two cell subsets,when
compared to vehicle and treatmentwith 4 μg/kg. (E) GP33–41 peptide stimulation of CD8+ T cells from LCMV-Cl 13-infectedmice results in reduced expression of TNF-α and IFN-γ compared to cells from LCMV-Arm53b infectedmice. (F) Similarly,
IL-2 and TNF-α are strongly produced in response to GP61–80 peptide stimulation from IFN-γ+ CD4+ T cells frommice infected with LCMV-Arm53b, but not with LCMV-Cl 13. Treatment with FTY720, at any dose, fails to modify the frequencies of
cytokine-producing CD8+ (E) or CD4+ (F) T cells. However, treating with FTY720 at 1 mg/kg, but not 4 μg/kg, decreases the number of IFN-γ-producing CD8+ (G) or CD4+ (H) T cells, in response to GP33–41 or GP61–80 peptide simulation,
respectively,when compared to VEH. (I)Micewere infectedwith 2×106 PFU LCMV-Cl 13 i.v. and treated i.v., once a day for 3 days, starting 1 h post-infection. Administration of FTY720 at 1mg/kg, but not 4 μg/kg, signiﬁcantly increases LCMV-Cl 13
burden in serumwhen compared to VEH (n=8–9 mice per group) on days 15 and 30 post-infection. Also 1 mg/kg of FTY720 enhances viral burden and delays LCMV-Cl 13 clearance from the serum on day 62 post-infection when compared to
vehicle-treated mice, but the difference is not statistically signiﬁcant. (A, C, E, and F) Representative density plots are shown; n≥4 mice per group; average±SEM; ⁎, pb0.05, signiﬁcantly different from VEH; #, pb0.09.
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264 K.B. Walsh et al. / Virology 397 (2010) 260–269infection (Fig. 3I). All mice treated with FTY720 had detectable virus
in the serum on day 62 post-infection while virus was undetectable in
four out of nine mice (44%) treated with vehicle demonstrating that
FTY720 treatment delays LCMV-Cl 13 clearance from the serum.
Similarly, administration of a medium dose of FTY720 (40 μg/kg) does
not affect viral burden within the serum of LCMV-Cl 13-infected mice
(data not shown), demonstrating that a large dose of FTY720 (1 mg/
kg) is required to increase viral burden in the serum. Experiments
performed in Balb/c mice yielded similar results (data not shown).
Thus, low dose of FTY720 (4 μg/kg) does not alter viral persistence or
T cell exhaustion while high dose of FTY720 (1 mg/kg) negatively
affects the antiviral immune response.
We next assessed the effects of FTY720 treatment during the
persistent phase of LCMV-Cl 13 infection. Mice were treated with
vehicle, 5 or 50 μg/kg of FTY720 i.v. on days 30, 31 and 32 post-
infection and monitored for serum viral burden. Viral load was
similar between vehicle- and FTY720-treated groups on days 44 and
51 post-infection, demonstrating that FTY720 administration does
not purge LCMV-Cl 13 from the blood (Fig. 4A). The spatiotemporal
course of LCMV-Cl 13 burden has previously been characterized
(Ahmed et al., 1984; Brooks et al., 2006; Moskophidis et al., 1995;
Wherry et al., 2003). In brief, LCMV-Cl 13 is detectable within the
serum and most organs until 70 days post-infection, but persists
within the brain until 100–120 days post-infection (Oldstone et al.,
1986) and within the kidneys for up to 2 years due to the formationFig. 4. FTY720 does not reduce viremia or virus titer in tissues of mice persistently
infected with LCMV-Cl 13. (A and B) Mice were infected i.v. with 2×106 PFU LCMV-Cl
13. Mice were treated with vehicle (VEH, shaded squares) and 5 (shaded circles) or
50 μg/kg (shaded triangles) of FTY720 on days 30, 31 and 32 post-infection. (A) Plaque
assays of serum samples from all cohorts display no signiﬁcant difference in viral titers.
n=4mice per group; data are represented as average±SEM. (B) Tissues harvested on
day 62 post-infection were used for determination of viral titer by plaque assay.
Differences between experimental groups are not statistically signiﬁcant. Circles
represent individual mice while bars indicate the group average. Experiments were
replicated three times by two independent groups, which obtained similar results.of LCMV-speciﬁc antibody immune complexes (reviewed by Old-
stone, 2006). According to Premenko-Lanier et al. (2008), virus was
purged from brain and kidney 30 days post-FTY720 administration,
i.e., 60 days post-infection. In contrast to these results, we detect
virus in both brain and kidney after treatment with 5 and 50 μg/kg of
FTY720 on day 62 post-infection, i.e., day 32 post-treatment (Fig. 4B).
Viral titers were equivalent in tissues regardless of the treatment
regimens. These results were also observed using a different vehicle
for FTY720 (0.1% fatty acid-free bovine serum albumin in PBS) to
increase drug solubility, and in another series of experiments using
Balb/c mice (data not shown). These data indicate that FTY720
treatment does not alleviate LCMV-Cl 13 persistence nor does it
signiﬁcantly alter viral burden within sera and tissues. Our observa-
tions of virus persisting in the brain and kidneys following FTY720
treatment are not surprising since reconstitution with immune
memory-speciﬁc antiviral LCMV T cells by adoptive transfer therapy,
while purging virus from sera by 15 days, takes over 100 days to clear
virus from the brain (Oldstone et al., 1986), and longer to clear virus
from the kidney (Oldstone et al., 1986).
S1P1-induced lymphopenia inhibits the generation of virus-speciﬁc
T cells
Phosphorylated FTY720 binds to four of the ﬁve S1P receptors
(S1P1 and S1P3–5). These receptors have redundant and non-
redundant functions and are differentially expressed on individual
immune cell populations. We utilized AUY954, an S1P1-speciﬁc
agonist previously shown to induce lymphopenia (Pan et al., 2006),
to assess how S1P1 signaling would affect LCMV-Cl 13 infection and
the development and functionality of virus-speciﬁc T cells. Mice were
infected with 2×106 PFU of LCMV-Cl 13 and treated with vehicle or
3 mg/kg of AUY954 by gavage 1 h and 1 and 2 days post-infection.
Virus-speciﬁc T cells from the spleen were analyzed on day 8 post-
infection using tetramer staining. AUY954 treatment does not
signiﬁcantly reduce the frequencies and numbers of virus-speciﬁc
CD8+ (Fig. 5A–C) and CD4+ (Fig. 5D) T cells. Infection with LCMV-Cl
13 results in reduced frequencies of IFN-γ+/TNF-α+ CD8+ T cells,
when compared to mice infected with LCMV-Arm53b (Fig. 5E and F).
Similarly, LCMV-speciﬁc CD4+ T cells from LCMV-Cl 13-infected mice
treated with AUY954 or vehicle express less TNF-α and IL-2 compared
to LCMV-Arm53b-infected mice (Fig. 5G). Although frequencies of
IFN-γ-producing cells are not drastically impaired (Fig. 5E–F; data not
shown), the absolute number of virus-speciﬁc CD8+ (Fig. 5H) and
CD4+ (Fig. 5I) T cells expressing IFN-γ is signiﬁcantly decreased by
AUY954, when compared to mice treated with vehicle. Lastly, LCMV-
Cl 13 titer within the serum on day 15, 30 and 62 post-infection
reveals that AUY954 treatment does not affect viral replication when
compared to mice treated with vehicle (Fig. 5J). Thus, AUY954
treatment does not alleviate T cell exhaustion, but hampers the
antiviral T cell response without signiﬁcantly affecting LCMV-Cl 13
viral burden.
Because LCMV-Cl 13 induces T cell exhaustion, it is difﬁcult to
interpret how sphingosine analogs negatively affect the antiviral
immune response. To establish how AUY954 treatment alters the
virus-speciﬁc CD8+ T cell response, mice that received 1×104
Thy1.1+ DbGP33–41 TCR-tg cells 1 day prior were infected with
1×106 PFU i.v. with an engineered A/WSN/33 (H1N1) inﬂuenza
virus bearing LCMV immunodominant epitopes H-2b CD8+ and I-Ab
CD4+ into the neuraminidase stalk (FLU-LCMV) (Marsolais et al.,
2009). AUY954 was administered by gavage on days 2 and 3 post-
infection, i.e., at the time of initial T cell–DC interactions in lymphoid
organs. On day 6 post-infection, there is a reduction in the
frequencies of virus-speciﬁc CD8+ T cells in the inguinal and
mediastinal lymph nodes, lung and spleen (Fig. 6A). This correlates
with a signiﬁcant reduction in the number of virus-speciﬁc CD8+ T
cells within the inguinal lymph node and spleen (Fig. 6B). Therefore,
Fig. 5. An S1P1-speciﬁc agonist does not alter T cell exhaustion, LCMV-Cl 13 viral burden, but hampers the antiviral T cell response. (A–J) Mice were infected i.v. with mock, 2×106 PFU LCMV-Cl 13 or 1×105 PFU LCMV-Arm53b i.p. (E–G) and
treated by gavage, daily for 3 days, starting 1 h post-infection, with vehicle (VEH) or 3 mg/kg AUY954. Spleens were harvested 8 days post-infection. Frequencies (representative dot plots) and numbers (bar graphs) of CD8+ GP33–41 (A),
NP396–404 (B), NP205–212 (C), tetramer positive and CD4+ GP65–77 (D) tetramer positive cells are increased in LCMV-Cl 13 infected mice (grey and black bars), compared to mock-infected mice (white bars). AUY954 treatment (black bars) does
not signiﬁcantly decrease frequencies or numbers of these T cell subsets, when compared to VEH (grey bars). In vitro stimulation with GP33–41 (E) or NP396–404 peptide (F) results in strong induction of TNF-α and IFN-γ production in CD8+ T
cells isolated frommice infected with LCMV-Arm53b, when compared to CD8+ T cells frommock-infected mice and LCMV-Cl 13-infected mice treated with VEH or AUY954. Similarly, in vitro simulation with GP61–80 (G) results in an increase
in TNF-α and IL-2 expression in IFN-γ+ CD4+ T cells isolated from LCMV-Arm53b-infected mice when compared to mock-infected and LCMV-Cl 13-infected mice treated either with VEH or AUY954. Numbers of IFN-γ producing CD8+ and
CD4+ T cells in response to in vitro GP33–41 (H) or GP61–80 (I) peptide stimulation, respectively, are signiﬁcantly decreased by AUY954 treatment, when compared to VEH. (J) Mice treated with VEH or AUY954 display similar serum virus titer
on days 15, 30 and 62 post-infection. Representative density plots are shown; nN4 mice per group; average±SEM; ⁎, pb0.05, signiﬁcantly different from VEH.
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Fig. 6. Treatment with the S1P1-speciﬁc agonist AUY954 interferes with the host's response to virus infection. (A and B) 1×104 GP33–41 TCR-transgenic Thy1.1+ CD8+ T cells were
adoptively transferred into mice 1 day before infection. FLU-LCMV (1×106 PFU) was administered i.v. and 3 mg/kg of AUY954 (AUY) or vehicle (VEH) was administered by gavage
on days 2 and 3 post-infection. (A) Reduced frequencies of virus-speciﬁc GP33–41 TCR-transgenic Thy1.1+ CD8+ T cells are detected by ﬂow cytometric analysis in the lungs,
mediastinal and inguinal lymph nodes as well as in the spleen of mice treated with AUY954, when compared to VEH. Representative density plots are shown. (B) Absolute numbers
of virus-speciﬁc CD8+ cells are signiﬁcantly decreased by AUY954 treatment in inguinal lymph nodes and spleen. n=4 mice per group; data are represented as average±SEM. ⁎,
p≤0.05, signiﬁcantly different from VEH.
266 K.B. Walsh et al. / Virology 397 (2010) 260–269treatment with an S1P1-speciﬁc agonist, AUY954, negatively affects
the generation of virus-speciﬁc CD8+ T cells during the acute phase
of a systemic infection.
Discussion
Here we compare the lymphopenic effect induced by infection
with a LCMV strain that generates an antiviral CTL response and
clears an acute viral infection (Arm53b) with a LCMV variant (Cl 13)
that fails to generate a vigorous CTL response to terminate an acute
infection causing a resultant persistence of virus. We also examine
the modulation of LCMV-Cl 13 infection by the sphingosine analog
FTY720 and an S1P1 receptor-speciﬁc agonist, AUY954. Our studies
make the following four points. First, transient treatment with a low
dose of FTY720 (4 μg/kg) does not signiﬁcantly modify viral burden
following infection with LCMV-Cl 13. This was conﬁrmed at two
different onsets of treatment, i.e., at the time of infection and during
the phase of persistence, as well as in two different MHC groups of
mice, H-2b: C57Bl/6 and H-2d Balb/c and by two separate groups
(Walsh, Marsolais, Rosen and Welch, Oldstone). Secondly, the extent
of lymphopenia induced by LCMV-Cl 13 and Arm53b is equivalent
over a dose range. Thirdly, LCMV-Cl 13-induded lymphopenia is
weakly enhanced by sphingosine analogs. Although the frequency of
T cells in the blood is signiﬁcantly reduced by FTY720 treatment
during LCMV-Cl 13 infection, the impact on the total number of
circulating T cells is minute since the virus induced a robust lympho-
penia by itself. Fourthly, treatment with a high dose of FTY720
(1 mg/kg, i.v.) or the S1P1-speciﬁc receptor agonist, AUY954 (3 mg/
kg, gavage), adversely affects the anti-LCMV T cell response and,
using inﬂuenza virus, impairs the generation of inﬂuenza virus-
speciﬁc CD8+ T cells.FTY720 does not signiﬁcantly alter the course of persistent virus
infection induced by LCMV-Cl 13. Our results agree with a recent
study that administration of FTY720 was ineffective at curing
macaques persistently infected with SIV:SHIVSF162P3 virus (Kersh
et al., 2009) and our results contrast with the report of Premenko-
Lanier et al. (2008) that transient FTY720-induced lymphopenia
successfully treated a persistent LCMV-Cl 13 infection and purged
virus from serum, brain and kidneys within 30 days after treatment.
The Premenko-Lanier and colleagues (2008) observations are difﬁcult
to reconcile with the literature since LCMV persists within kidneys for
up to 2 years due to the formation of virus–antibody immune
complexes and in the brain for over 100 days after adoptive transfer of
anti-LCMV-speciﬁc memory T cells that is able to clear virus from sera
by 15 days (Garidou et al., 2009; Oldstone et al., 1986).
Previous studies support the spleen to be a primary site of T cell
inactivation. During LCMV clone-13 infection, B cells and spleen DC
were shown to up-regulate the production of the immunosuppressive
molecule IL-10 (Brooks et al., 2006, 2008). In addition, expression of
the immunosuppressive receptor, programmed death-1 (PD-1), is
enhanced on LCMV-speciﬁc CD8+ T cells located within the spleen
following LCMV-Cl 13 infection (Barber et al., 2006). Since FTY720
eliminates naïve and activated T cells from spleen and peripheral
organs (Hofmann et al., 2006; Sawicka et al., 2003) by sequestration
into lymph nodes and Peyer's patches (Mandala et al., 2002; Sanna et
al., 2004), one could speculate that this alteration of cellular
distributionmight allow restoration of T cell function. In contradiction
with this hypothesis, our results demonstrate that administration of
FTY720 at doses sufﬁcient to enhance LCMV-Cl 13-induced lympho-
penia does not have an effect on T cell exhaustion or viral persistence,
suggesting that soluble factors like IL-10 could maintain T cell
exhaustion outside of the spleen and/or that the PD-1/PD-L1 pathway
267K.B. Walsh et al. / Virology 397 (2010) 260–269is effective in lymph nodes or Peyer's patches. Furthermore, our
results show that the extent of lymphopenia induced after LCMV-Cl
13 infection is not related to persistence of LCMV-Cl 13, since infection
with the non-persisting strain of LCMV (Arm53b) induces the same
degree of lymphopenia.
Acute lymphopenia is independent of infection by LCMV-Arm53b
or -Cl 13 and can be enhanced by FTY720. In this study, we ﬁnd that
infection with LCMV-Arm53b and -Cl 13 induced profound lympho-
penia (Figs. 1 and 2), and that the extent of lymphopenia induced
by these two viruses is equivalent 3 days following infection. Early
after viral infection, proinﬂammatory cytokines such as type I inter-
ferons (Kamphuis et al., 2006) and tumor necrosis factor-α (Young
et al., 2000) induce the retention of T cells in draining lymphoid
organs. Importantly, LCMV-Arm53b and -Cl 13 induce the release of
type I interferon in similar amounts in serum early after infection
(Zuniga et al., 2008), which could explain the similar levels of lym-
phopenia induced by both LCMV variants. Virus-induced lym-
phopenia is, at least partially, due to type-I interferon-induced
CD69 up-regulation on the surface of T cells (Shiow et al., 2006).
However, FTY720 can down-modulate the expression of CD69 on
the surface of T cells (Rosen et al., 2003), arguing that enhance-
ment of LCMV-induced lymphopenia by FTY720 may likely act
through a different mechanism. Together, these results favor a
model where enhancement of lymphopenia by FTY720 during viral
infection is due to enforcement of the endothelial barrier in the
lymph node, as previously observed in naïve mice (Mandala et al.,
2002; Wei et al., 2005). This is further supported by our observation
that the S1P1 receptor-speciﬁc agonist AUY954, which is sufﬁcient
in inducing lymphopenia and tighten the endothelial barrier
(Marsolais and Rosen, 2009), disrupts the T cell response via S1P1
receptor activation.
We ﬁnd that sphingosine analogs can alter the antiviral immune
response. Low doses (4 and 40 μg/kg) of FTY720, a precursor of the
S1P1 and S1P3–5 agonist, FTY720-phosphate, administered at the
time of infection does not affect the antiviral T cell response or viral
burden within the serum. However, treatment with 1 mg/kg of
FTY720, a dose previously shown to induce lymphopenia in mice,
results in increased serum viral burden on days 15, 30 and 62 post-
infection which correlates with a signiﬁcant reduction in the numbers
of LCMV-speciﬁc T cells and the number of IFN-γ producing T cells
following peptide stimulation. The reduction in LCMV-speciﬁc T cells
following FTY720 treatment is at least partially due to S1P1 signaling
since treatment with the S1P1-speciﬁc agonist, AUY954, signiﬁcantly
reduces the number of IFN-γ producing cells. However, the negative
antiviral effect FTY720 exerts appears to be due to the multipotent
activities of this drug as S1P1 receptor-speciﬁc signaling fails to
replicate the effect of FTY720 on viral burden. This observation is not
surprising as FTY720 was previously shown to interact with many
targets including S1P lyase (Bandhuvula et al., 2005), lipid phosphate
phosphatase (Mechtcheriakova et al., 2007) and sphingosine kinases
(Billich et al., 2003). In agreement with a previous report (Pinschewer
et al., 2000), our data reveal that sphingosine analogs alter the distri-
bution of T cells during LCMV infection. In addition, we provide
evidence that high doses of FTY720 as well as S1P1-induced lympho-
penia during the acute phase of an infection hinder the expansion of
virus-speciﬁc T cells.
Our data agree with other studies demonstrating that immuno-
suppressive drugs result in reactivation of viruses, normally latent,
due to suppression of viral replication by the host's immune system.
For instance, cyclosporine has resulted in the recrudescence of
hepatitis B virus and Epstein-Barr virus in organ recipients (Ho et al.,
1997; Seth et al., 2002) and anti-α4-integrin antibody, natalizumab,
has caused progressive multifocal leukoencephalopathy by reactivat-
ing JC virus (Langer-Gould et al., 2005). FTY720 does not appear to be
an exception to this rule. Recently, a patient on FTY720 phase III trials
for multiple sclerosis died from recrudescence of varicella zosterwhile another suffered herpes virus-mediated encephalitis (Garber,
2008). Sphingosine analogs have negative antiviral affects in rodent
models as well. The S1P1 receptor-speciﬁc agonist, SEW2871, was
shown to reduce cytokine secretion in CD4+ T cells during diabetes
(Srinivasan et al., 2008). Also, CD4+ T cells from S1P1 transgenic mice
expressed high levels of IL-4 suggesting S1P1 induces a Th2 cytokine
proﬁle that would be deleterious for an antiviral response (Wang et
al., 2007). Differences in pharmacokinetics of the different drugs may
also account for the slight differences seen between FTY720 and
AUY954 treatments of LCMV-Cl 13-infected mice. Nonetheless, our
data demonstrate that induction of lymphopenia via S1P1 receptor
signaling negatively affects the immune response against two viral
pathogens, i.e., LCMV and inﬂuenza, by hampering the generation of
virus-speciﬁc T cells.
Taken together, our work does not support acute lymphopenia as a
predictive or therapeutic parameter for persistent viral infections.
Instead, we show that FTY720, or S1P1-speciﬁc agonist AUY954, can
negatively affect the host's ability to respond to viral infection.
Materials and methods
Mice and viruses
C57Bl/6, Balb/c and C57Bl/6 Thy1.1+ DbGP33–41 TCR-tg male mice
(P14) (6–8 weeks of age) were used. All mice were maintained in
pathogen-free conditions and handling conforms to the requirements
of the National Institutes of Health and The Scripps Research Institute
animal research committee. Isolation of CD8+ T cells and T cell
adoptive transfers were performed as described (Marsolais et al.,
2009). LCMV-Cl 13 and -Arm53b strains were grown, stored and
quantiﬁed according to published methods (Borrow et al., 1995).
Generation and growth of mutant inﬂuenza A/WSN/33 H1N1 virus
containing T cell-speciﬁc GP33 and GP65 LCMV sequences in its
neuraminidase stalk (FLU-LCMV)was described elsewhere (Marsolais
et al., 2009).
Mononuclear cell isolation
Cells were obtained by mechanically disrupting the spleens, lungs,
inguinal and mediastinal lymph nodes through a 100-μm ﬁlter. Before
lungs were removed, mice were perfused with 10 ml of phosphate
buffered saline (PBS; Invitrogen, Carlsbad, CA) via cardiac puncture.
Red blood cells were lysed by treating splenocytes and lungs with red
blood cell lysis buffer (ammonium chloride: 0.02 M Tris–HCl, 0.14 M
NH4Cl), washed and resuspended in cell culture medium. For analysis
of lymphopenia, 350 μl of blood was harvested via cardiac puncture
and placed in 10 ml of red blood cell lysis buffer for 1 h on ice.
Peripheral blood mononuclear cells (PBMCs) were centrifuged and
then subjected to a second round of red blood cell lysis (3 min at rt).
Cells were collected by centrifugation and resuspended in a known
volume of PBS. The number of viable cells per tissue or volume of
blood was obtained by the use of a hemocytometer and the trypan
blue exclusion method.
Formulation and administration of compounds
All experiments concerning FTY720 were performed in accor-
dance with the previous study by Premenko-Lanier et al. (2008). In
short, FTY720 (Cayman Chemical, Ann Arbor, MI) was dissolved in
DMSO and stored at −20 °C. On the day of the experiment, stock
solution was diluted in water to obtain working concentrations in
a ﬁnal volume of 200 μl. In parallel experiments, PBS containing
0.1% BSA was used to dilute DMSO stock of FTY720. Results ob-
tained with both formulations were identical (data not shown). Mice
were administered i.v. with indicated doses of FTY720 once a day,
for 3 days, starting 1 h after infection. For FTY720 treatment of
268 K.B. Walsh et al. / Virology 397 (2010) 260–269persistently infected mice, mice were treated on days 30, 31 and 32
post-infection. AUY954 (gifted by Dr. Nathanael S. Gray, Dana-
Farber Hospital, Boston, MA) was dissolved in a 1:1 mixture of
PEG300 and 5% dextrose and administered by gavage at a dose of
3 mg/kg.
Plaque assays
Blood was drawn from the retro-orbital sinus under isoﬂurane
anesthesia. Serum was isolated by centrifugation to remove red and
white blood cells. Serum (10 or 100 μl) was used to perform 10-fold
serial dilutions for plaque assays on VERO cells (Ahmed et al., 1984).
Brains and kidneys were harvested from mice euthanized on day 62
post-infection and frozen at −80 °C. At the time of the assay, tissues
were thawed, homogenized and centrifuged and 100 μL of the
supernatant was used to perform 10-fold serial dilutions for plaque
assays (Ahmed et al., 1984).
Cell surface staining
Mononuclear cells were stained with antibodies raised against
murine CD4 Paciﬁc Blue (L3T4; eBioscience, San Diego, CA), CD8 APC
(53-6.7; BD Biosciences, San Jose, CA), CD19 FITC (1D3; BD
Biosciences, San Jose, CA), CD11b PE-Cy7 (M1/70; eBioscience, San
Diego, CA), CD45.2 Alexa Fluor 750 (104; eBioscience, San Diego, CA)
and CD90.1 FITC (HIS51; eBioscience, San Diego, CA) as described
(Walsh et al., 2008). For tetramer staining, mononuclear cells
were incubated for 1 h on ice with MHC class I tetramers for
DbGP33–41 APC, DbNP396–404 APC and KbNP205–212 APC. MHC II
tetramer staining with I-AbGP65–77 APC was performed for 1 h at
room temperature. Biotinylated monomers were obtained from the
NIH Tetramer Core Facility and tetramerized using streptavidin-APC
(Invitrogen, Carlsbad, CA).
Intracellular cytokine staining
Splenocytes were stimulated for 5 h with 2 μg/ml of the MHC class
I restricted LCMV-GP33–41, LCMV-NP396–404, or the MHC class II
restricted peptide LCMV-GP61–80 peptide (N99% pure; The Scripps
Research Institute, Center for Protein Science, La Jolla, CA) in the
presence of 50 U/ml recombinant murine IL-2 (R&D Systems,
Minneapolis, MN) and 4 μg/ml brefeldin A (Sigma, St. Louis, MO).
Cells were ﬁxed, permeabilized and stained intracellulary with
antibodies to TNF-α FITC (MP6-XT22; BD Biosciences, San Jose, CA),
IFN-γ PE (XMG1.2; BD Biosciences, San Jose, CA) and IL-2 APC (JES6-
5H4; BD Biosciences, San Jose, CA). Flow cytometric analysis was
performed using Digital LSR II (Becton Dickinson) and data were
analyzed using FlowJo (Tree Star, Inc., Ashland, OR). Absolute number
of cells was determined by multiplying the frequency of speciﬁc cell
populations by the total number of viable cells.
Statistics
Data are presented as means±SEM. ANOVA or unpaired two-
tailed Student's t-test was used, when appropriate, to determine
signiﬁcance, which was set at 5%.
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